The Indian biosimilar drugs industry is poised for exponential growth owing to the increasing acceptance, entry of new players, and successful launch of biosimilar products.
The comment was made by CPhI Conferences, a division of UBM India, which hosts a number of successful pharmaceutical conferences in the country has announced the 2nd Annual Biosimilars Congress India 2017, slated for August 8-9 in Hyderabad
Indian biosimilar manufacturers are striving to tap this growing opportunity through heavy investments and acquisitions. While biosimilars offer great opportunities to the India pharma and biopharma industry, manufacturers also face some unique R&D challenges. With the introduction of a new regulatory policy in India and increased affordability that biosimilars offer, Indian pharmaceutical companies have started to look at biosimilars as a lucrative sector. The domestic market is expected to grow at an accelerated pace by aiming to reach a target of $40 billion by 2030 and commanding around 20% share of the global market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze